Technology Transfer

Case Western Reserve University's Technology Transfer Office (TTO) serves our innovators with full-spectrum intellectual property services. For both faculty and students, we provide support for intellectual property and commercialization that spans the research & development continuum. We serve our researchers by assessing and building upon the commercial potential of new ideas and inventions.

Through interaction with our inventors, regional and national networks, including our affiliate healthcare systems, and potential commercial partners, we endeavor to determine the best path of translation and ultimate commercialization for University intellectual assets.

Consistent with the University's mission, the Technology Transfer Office is working towards enhancing its role in the promotion of an inclusive culture of global citizenship by exploring issues of access to essential medicines by resource-limited countries. This work includes moving towards the Universities Allied for Essential Medicine's Global Access Licensing Framework.

Recent News

New company from Case Western Reserve University helps medical students learn anatomy through holographic imagery
--Ideastream Public Media, January 26, 2023

Case Western Reserve University launches Ilumis: Startup to accelerate and scale adoption of pioneering HoloAnatomy software to transform the way students learn human anatomy
--CWRU Daily, January 17, 2023

Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research
--PAVmed, December 1, 2022

Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry
--PAVmed, December 8, 2022

Please visit our TTO News webpage for more articles and press releases about TTO success stories.


For Questions About...

  • Your Invention Disclosure Form (IDF), please contact Joy Chen at 216.368.0362.
  • A Material Transfer Agreement (MTA) please contact Tyler Gray at 216.368.1401.
  • A Data Use Agreement (DUA), please contact
  • Anything else, please contact Daniel Pendergast at 216.368.0184.